Genomind
PrivateLast Round
Series D
Jan 29, 2021
Total Funding Raised
$20.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Genomind operates in Healthcare & Life Sciences and is based in King of Prussia, Pennsylvania. Its latest recorded funding round was a Series D round in January 2021.
Genomind is a precision health company that specializes in mental healthcare, providing genetic testing and a biotechnology platform to aid in personalized treatment. The company's main offerings, including the Genomind Professional PGx Express and the direct-to-consumer Mental Health Map, analyze a patient's genetic makeup to provide insights on how they may respond to different medications for psychiatric conditions. This enables healthcare professionals to reduce trial-and-error in medication selection and develop more targeted treatment plans. Founded in 2009 by Dr. Ronald Dozoretz, Genomind aims to optimize the treatment experience for individuals and providers through actionable genetic insights and innovative health technology.
Sector
Healthcare & Life Sciences
Verticals
Mental Health, Precision Medicine, Biotechnology, Healthcare Analytics
Business Model
B2B2C
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genomind Comparables
Compare Genomind with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Myriad Genetics | 86% | |
| Castle Biosciences, Inc. | 85% | |
| OneOme | 81% |
For institutional investors. Book with your work email.
Genomind Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jan 29, 2021 | ||||
| Series B | Feb 8, 2017 | ||||
| VC Round | Sep 22, 2015 | ||||
| Series A | Apr 9, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Genomind Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Claritas Capital | Series D, Series A, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 10, 2026
Successfully treated over 500,000 patients.
For institutional investors. Book with your work email.
Genomind Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genomind's valuation, stock price, and market status.
Is Genomind a public or private company?
Genomind is a private company.
What is the current stock price of Genomind?
Genomind is a private company, so its shares have no public market price. Caplight tracks Genomind's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genomind worth (valuation)?
Valuation information for Genomind is not publicly available.
Can I buy Genomind stock?
Genomind shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genomind's last funding round?
Genomind's most recent funding round was Series D on January 29, 2021.
Who are the main investors in Genomind?
Key investors in Genomind include Claritas Capital.
Will Genomind IPO soon?
No public IPO plans have been announced for Genomind.
How can I track Genomind secondary market activity?
Caplight tracks bids, offers, and trades in Genomind's shares on secondary markets.